Keywords: update, nasso, conference, hears, encouraging, data, gsk

UPDATE: 2007 NASSO conference hears encouraging data on GSK's alli, Orexigen's Contrave et al

Article | 29 October 2007

Print This

In the face of growing concerns about an obesity epidemic, weight-loss drugs, with their high margins, are an attractive target ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in